2m 2m 2m 2m 2m 2m 2m
RANI THERAP-A (RANI)
NASDAQ
$0.86-$0.02 (-2.30%)
Price as of Jun 03, 2026 7:44 PM EDT- $106.9MMarket Cap
- 56.30%1-Year Change
- BiotechnologyIndustry
RANI THERAP-A (RANI)
$0.86-$0.02 (-2.30%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 1.6M +58.85% | 1.0M N/A | N/A N/A | 0 -100.00% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 1.6M +58.85% | 1.0M N/A | 0 N/A | 0 -100.00% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -20.2M -24.27% | -26.7M -32.66% | -39.6M +8.24% | -36.6M +38.23% | |
Depreciation and Amortization Expense | 900,000 -12.45% | 1.0M +25.06% | 822,000 +50.00% | 548,000 +10.26% | |
Total Operating Expenses | 39.9M -26.50% | 54.3M -17.79% | 66.1M +4.17% | 63.5M +216.82% | |
Operating Profit | -38.3M -28.14% | -53.3M -19.34% | -66.1M +4.17% | -63.5M +22.97% | |
Interest Income | 827,000 -53.09% | 1.8M -46.59% | 3.3M +164.50% | 1.2M +1,302.25% | |
Interest Expense | -2.9M -42.56% | -5.0M -1.02% | -5.1M +374.79% | -1.1M +129.83% | |
Interest Income and Expense and Net | -2.1M -36.88% | -3.3M +83.30% | -1.8M -1,107.91% | 177,000 +146.95% | |
Total Nonoperating Income and Expense | 2.9M -42.56% | 5.0M -1.02% | 5.1M +374.79% | 1.1M +129.83% | |
Income before Taxes | -38.3M -28.14% | -53.3M -21.46% | -67.9M +7.28% | -63.3M +19.28% | |
Income Taxes | 0 N/A | 0 N/A | 0 -100.00% | 70,000 +70.73% | |
Extraordinary Items | 0 -100.00% | 3.7M N/A | N/A N/A | N/A N/A | |
Net Income | -29.7M -1.15% | -30.0M -11.63% | -34.0M +11.06% | -30.6M +267.16% | |
Net Income from Continuing Operations Applicable to Common | -29.7M -1.15% | -30.0M -55.78% | -67.9M +7.28% | -63.3M +19.28% | |
Basic EPS and Net Income | -0.45 -57.14% | -1.05 -21.05% | -1.33 +3.91% | -1.28 +197.67% | |
Diluted EPS and Net Income | -0.45 -57.14% | -1.05 -21.05% | -1.33 +3.91% | -1.28 +197.67% | |
Basic Weighted Average Shares | 66,138 +132.26% | 28,476 +11.65% | 25,505 +7.09% | 23,817 -99.88% | |
Diluted Weighted Average Shares | 66,138 +132.26% | 28,476 +11.65% | 25,505 +7.09% | 23,817 -99.88% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 18.6M +394.90% | 3.8M -35.85% | 5.9M -78.29% | 27.0M -77.01% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | 98.5M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 18.6M +394.90% | 3.8M -35.85% | 5.9M -95.33% | 125.5M +6.86% | |
Total Current Assets | 53.3M +79.27% | 29.7M -41.50% | 50.8M -49.62% | 100.9M -15.61% | |
Accumulated Depreciation | 5.5M +19.40% | 4.6M +26.40% | 3.7M +28.85% | 2.8M +22.22% | |
Property and Plant and Equipment and Net | 736,000 -52.45% | 1.5M -74.64% | 6.1M +1.11% | 6.0M +30.92% | |
Total Long-Term Assets | 246,000 0.00% | 246,000 0.00% | 246,000 -99.68% | 77.5M +1,580.68% | |
Total Assets | 58.6M +60.02% | 36.6M -36.75% | 57.9M -46.39% | 108.0M -13.03% | |
Income Taxes Payable | N/A N/A | 0 N/A | 0 -100.00% | 2.3M +60.11% | |
Total Short-Term Debt | 0 -100.00% | 15.0M +206.31% | 4.9M +9,139.62% | 53,000 -57.94% | |
Total Current Liabilities | 12.7M -36.31% | 19.9M +148.98% | 8.0M +65.92% | 4.8M +82.39% | |
Total Long-Term Debt | 0 -100.00% | 9.6M -60.74% | 24.5M -16.00% | 29.1M N/A | |
Total Long-Term Liabilities | 4.4M -66.49% | 13.3M -45.88% | 24.5M -16.17% | 29.2M N/A | |
Total Liabilities | 17.1M -48.38% | 33.1M +2.06% | 32.5M -4.56% | 34.0M +1,188.75% | |
Retained Earnings | -132.6M +28.83% | -102.9M +41.18% | -72.9M +87.28% | -38.9M +367.16% | |
Total Stockholders Equity | 33.0M +1,557.13% | 2.0M -84.52% | 12.9M -65.09% | 36.9M -22.26% | |
Total Shares Outstanding | 97.6M +192.02% | 33.4M -66.67% | 100.3M +1.50% | 98.8M +0.83% | |
Cash Flow | |||||
Cash from Operating Activities | -18.7M -47.28% | -35.5M -30.72% | -51.2M +10.15% | -46.5M +44.25% | |
Capital Expenditures | 88,000 -67.16% | 268,000 -78.19% | 1.2M -24.09% | 1.6M +219.96% | |
Cash from Investing Activities | -7.0M -135.49% | 19.8M -33.66% | 29.9M +141.22% | -72.4M +14,215.42% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 40.3M +196.65% | 13.6M +5,730.47% | 233,000 -99.20% | 29.0M -62.40% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -2,345.99% -54.76% | -5,186.19% N/A | N/A N/A | N/A N/A | |
Return on Assets | -62.30% -1.88% | -63.50% +55.09% | -40.94% +55.42% | -26.34% N/A | |
Return on Equity | -169.55% -58.04% | -404.07% +195.71% | -136.64% +88.22% | -72.60% N/A | |
Revenue Growth | 58.85% N/A | N/A N/A | N/A N/A | -100.00% N/A | |
Current Ratio | 4.21 +181.47% | 1.50 -76.51% | 6.36 -69.63% | 20.96 N/A | |
Cash Ratio | 1.47 +677.15% | 0.19 -74.24% | 0.73 -86.91% | 5.61 N/A | |
Debt-to-Equity Ratio | 0.00 -100.00% | 12.36 +441.07% | 2.28 +188.22% | 0.79 N/A | |
Debt-to-Assets Ratio | 0.00 -100.00% | 0.67 +32.45% | 0.51 +87.68% | 0.27 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow